Name: 글로벌 시장 동향
SKU: BT7394
Availability: InStock

보고서 요약(국문)

개요
전 세계 아데노 관련 바이러스(AAV) 벡터 제조 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
아데노 관련 바이러스(AAV) 벡터는 복제 불능의 단일 가닥 DNA 파르보바이러스로, 복제를 위해 보조 아데노바이러스(Helper Ad)가 필요합니다. 보조 바이러스 없이 숙주 세포 게놈에 특정 부위 또는 무작위로 AAV 벡터가 통합되면 장기간 유전자 발현이 가능합니다. 또한, 아데노 관련 바이러스 벡터는 다양한 휴면 및 분열 표적 세포에서 높은 형질전환 효율을 나타냅니다. 아데노바이러스와 달리 AAV 벡터는 유의미한 면역 반응을 유발하지 않습니다.
더 나아가, 아데노 관련 바이러스 벡터는 유전 질환 및 암에 대한 유전자 치료에 더욱 활발하게 사용되고 있습니다. 또한, 아데노 관련 바이러스 벡터를 이용한 유전자 전달은 유전성 실명 및 척수근육위축증 치료, 장기 치료 효과, 그리고 혈우병 및 뒤센 근육 dystrophy를 포함한 기타 희귀 질환 치료에도 승인되었습니다. 이러한 기술은 다양한 질병 치료를 위한 세포 치료 및 백신 생산에도 활용되고 있습니다.
시장 동향: 성장 요인
아데노 관련 바이러스 벡터의 채택 증가
아데노 관련 바이러스 벡터의 채택이 증가함에 따라 예측 기간 동안 시장 성장이 촉진될 것으로 예상됩니다. 채택 증가로 인해 더 많은 제조 플랫폼 출시가 주목받고 있습니다. 예를 들어, AGC Biologics는 2023년 5월 16일에 BravoAAV 및 ProntoLVV 바이러스 벡터 플랫폼을 출시했습니다. 30년 이상 축적된 렌티바이러스 벡터(LVV) 및 아데노 관련 바이러스 벡터(AAV) 개발, 제조 및 분석 경험을 바탕으로 개발된 AGC Biologics의 새로운 플랫폼은 신속하고 효율적이며 재현 가능한 임상 및 상업용 GMP 생산 및 출시를 제공합니다.

또한, 2022년 10월 10일, Charles River Laboratories International, Inc.는 nAAVigation 벡터 플랫폼(nAAVigation)을 출시했습니다. Charles River는 수십 년간 축적된 아데노 관련 바이러스(AAV) 벡터 위탁 개발 및 제조(CDMO) 경험과 생물학적 제제 시험 전문성을 바탕으로, 복잡한 공정 개발 없이도 GMP AAV 벡터 제조 경로를 간소화하는 플랫폼을 구축했습니다.
더욱이, 아데노 관련 바이러스 벡터는 다양한 질병 치료에 널리 사용되고 있어 그 활용도가 더욱 높아지고 있습니다. 예를 들어, 2023년 3월 2일에는 Spark Therapeutics의 시력 상실 치료제 Luxturna와 Novartis의 척수근육위축증 치료제 Zolgensma가 FDA의 임상 사용 승인을 받은 최초의 벡터 전달 유전자 치료제로 선정되었습니다. 이러한 승인은 유전자 치료 전달 기술에 대한 수요 급증을 가져왔으며, 이러한 수요 급증은 현재까지도 지속되고 있습니다. 현재 이러한 추세는 벡터 설계 및 제조 분야의 혁신을 촉진하고 있습니다.

또한, 아데노 관련 바이러스 벡터는 유전자 치료에 가장 일반적으로 적용되며, 이는 채택률을 더욱 높이는 요인입니다. 예를 들어, 2023년 3월 9일, Charles River Laboratories International, Inc.는 아데노 관련 바이러스(AAV) 기반 유전자 치료 프로그램의 초기 연구 단계부터 상업 생산에 이르기까지 공급을 확보하고 프로세스를 간소화하도록 설계된 기성품 pHelper를 출시했습니다.
더 나아가, 유전 질환, 감염성 질환, 신경 질환, 안과 질환 및 기타 만성 질환의 유병률 증가, FDA 승인 건수 증가, 임상 시험 증가, 질병에 대한 인식 제고, 그리고 새로운 치료법과 백신 개발의 진전은 예측 기간 동안 시장 성장을 견인할 것으로 예상되는 요인입니다.
제한 요인
높은 제조 비용, 숙련된 전문가 부족, 제한된 클로닝 용량과 같은 요인은 시장 성장을 저해할 것으로 예상됩니다.
세분화 분석
글로벌 아데노 관련 바이러스 벡터 제조 시장은 제조 방법, 적용 분야, 치료 영역, 최종 사용자 및 지역별로 세분화됩니다.

유전자 치료 부문은 아데노 관련 바이러스(AAV) 벡터 제조 시장 점유율의 약 43.2%를 차지했습니다.
유전자 치료 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 아데노 관련 바이러스(AAV) 벡터는 다양한 인간 질병 치료를 위한 유전자 전달의 주요 플랫폼입니다. 아데노 관련 바이러스(AAV) 벡터는 현재 유전자 치료에 가장 많이 사용되는 바이러스 벡터 중 하나입니다. 많은 기업들이 유전자 치료를 위한 아데노 관련 바이러스 벡터 제조에 집중하고 있습니다.
예를 들어, 유전자 및 세포 치료를 위한 바이러스 벡터 기반 유전자 전달 기술 분야의 세계적인 선도 기업인 시리온 바이오테크(SIRION Biotech GmbH)는 2021년 2월 23일, 세계적인 바이오 제약 회사인 사노피(Sanofi)와 주요 인체 장기에 영향을 미치는 질환에 대한 효과적인 유전자 치료법을 실현하기 위해 개선된 조직 선택적 아데노 관련 바이러스(AAV) 벡터를 개발하기 위한 라이선스 및 협력 계약을 체결했습니다.

또한, 2023년 8월 1일, 워터스 코퍼레이션(Waters Corporation)은 유전자 치료제, 특히 아데노 관련 바이러스(AAV) 벡터의 분석을 개선하고 비용을 절감하기 위해 개발된 새로운 크기 배제 크로마토그래피(SEC) 컬럼 제품군을 처음으로 선보였습니다. 새로운 워터스 XBridge Premier GTx BEH SEC 컬럼은 AAV의 효능 및 안전성 측정 속도를 두 배로 높이고 이러한 새로운 유전자 전달체의 제조를 최적화합니다.
더욱이, 아데노 관련 바이러스 벡터는 연구자들이 다양한 심각한 질환을 치료하는 유전자 치료법을 개발하는 데 도움을 줍니다. 예를 들어, 더 건강한 세상을 위한 혁신에 전념하는 글로벌 리더인 퍼킨엘머(PerkinElmer, Inc.)는 2022년 11월, 다양한 심각한 질병에 대한 유전자 치료법을 연구하는 연구자들을 지원하기 위해 바로 사용할 수 있는 아데노 관련 바이러스 벡터(AAV) 검출 키트를 출시했습니다. 이 고처리량 바이러스 분석법은 연구자들이 생산 중인 바이러스 벡터 입자를 신속하고 쉽게 특성화하여 안전하고 효율적인 유전자 전달을 위한 의사 결정을 내릴 수 있도록 설계되었습니다.

지리적 분석
북미 지역은 시장 점유율의 약 40.3%를 차지했습니다.
북미 지역은 주요 기업들의 강력한 입지와 활발한 연구 활동에 힘입어 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 특히 미국을 중심으로 생명공학 기업과 제약 회사 등 주요 기업들이 활발하게 활동하고 있습니다. 이들 주요 기업들은 비용 효율성 등의 이점을 제공하며 더욱 발전된 아데노 관련 바이러스(AAV) 벡터 생산에 적극적으로 투자하고 있습니다.
예를 들어, 세계적인 과학 서비스 기업인 Thermo Fisher Scientific은 2022년 11월 16일, 임상 및 상업적 요구를 충족하는 데 도움이 되는 새로운 올인원 솔루션인 Gibco CTS AAV-MAX Helper-Free AAV Production System을 출시했습니다. 이 제품은 대규모 적용을 가능하게 하는 cGMP 조건에서 제조되는 유일한 제품입니다.
또한, 이 지역의 연구 활동 증가는 유전자 치료에 더욱 유리한 발전된 바이러스 벡터 생산에 기여하고 있습니다. 연구 활동이 증가함에 따라 유전자 치료법은 더욱 정밀하게 개발되어 다양한 질병에 대한 폭넓은 치료 옵션을 제공함으로써 환자의 치료 결과가 향상되고 있습니다.
예를 들어, 생명과학 기업으로 생물공정 기술 분야를 선도하는 Repligen Corporation은 2022년 2월 15일 유전자 치료제 제조 워크플로우에 사용되는 세 가지 첨단 친화성 크로마토그래피 수지를 출시했습니다. AVIPure - AAV9, AVIPure - AAV8, AVIPure - AAV2 수지는 Repligen의 자회사인 Avitide LLC에서 개발했으며, 주요 아데노 관련 바이러스(AAV) 유전자 치료 벡터에 특화되어 있습니다.
경쟁 환경
아데노 관련 바이러스 벡터 제조 시장의 주요 글로벌 업체로는 Thermo Fisher Scientific Inc., Oxford Biomedica PLC, Lonza Ltd, uniQure N.V., FUJIFILM Diosynth Biotechnologies, SIRION Biotech GmbH, Curigin Inc., Pfizer Inc., Genscript Biotech Corp, Vector Biolabs 등이 있습니다.

주요 개발 사항
• 2023년 3월 27일, cGMP 인증을 받은 위탁 개발 및 제조 조직(CDMO)인 Avirmax CMC Inc.는 재조합 아데노 관련 바이러스 벡터(rAAV) 생산을 위해 개발한 새로운 Sf 랍도바이러스 무첨가 세포주(일반명칭 Sf-RVF)를 도입했습니다.

• 2023년 8월 30일, Quest Diagnostics는 자사의 아데노 관련 바이러스(AAV) 검사인 AAVrh74 ELISA 분석법(CDx)에 대해 미국 식품의약국(FDA)으로부터 혁신 의료기기 지정을 받았습니다. 혁신 의료기기 지정은 생명을 위협하거나 돌이킬 수 없는 장애를 유발하는 질병 또는 질환에 대한 보다 효과적인 치료 또는 진단을 제공하는 특정 의료기기 및 기기 기반 복합 제품의 개발 및 검토를 신속하게 진행하기 위해 FDA에서 마련한 절차입니다.

• 2022년 6월 15일, Exothera SA는 LogicBio Therapeutics 및 Polyplus-transfection SA와 협력하여 200리터에서 2,000리터 용량의 고도로 확장 가능한 AAV 제조 플랫폼을 개발했습니다.
COVID-19 영향 분석
COVID-19 팬데믹은 전 세계 아데노 관련 바이러스 벡터 제조 시장에 상당한 영향을 미쳤습니다. 팬데믹으로 인해 아데노 관련 바이러스 벡터, 특히 COVID-19 백신 개발 및 생산에 대한 수요가 급증했습니다. 백신 개발을 지원하기 위한 이러한 벡터의 대규모 생산에 대한 긴급한 필요성이 수요 증가로 이어졌습니다.
예를 들어, 미국 국립보건원(NIH)은 2022년 연구를 통해 SARS-CoV-2 스파이크 단백질(S 단백질)의 이량체 수용체 결합 도메인(RBD)을 발현하는 9형 아데노 관련 바이러스 벡터 백신 후보를 개발하고 생쥐 모델에서 면역원성을 평가했습니다. AAV9-RBD 바이러스라는 이름의 이 백신 후보는 9형 아데노 관련 바이러스의 게놈에 링커로 간격을 두고 두 개의 RBD 사본의 N-말단에 신호 펩티드를 삽입하여 구성되었습니다.
시장 세분화
방법별
• 생체 내(In Vivo)
• 시험관 내(In Vitro)
적용 분야별
• 유전자 치료
• 세포 치료
• 백신 생산
• 기타
치료 영역별
• 유전 질환
• 감염성 질환
• 신경계 질환
• 혈액 질환
• 안과 질환
• 기타
최종 사용자별
• 제약 회사
• 생명공학 회사
• 학술 및 연구 기관
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
보고서 구매 이유

• 방법, 적용 분야, 치료 영역, 최종 사용자 및 지역별 글로벌 아데노 관련 바이러스 벡터 제조 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.
• 모든 세그먼트를 포함한 아데노 관련 바이러스 벡터 제조 시장 수준의 다양한 데이터가 담긴 엑셀 자료를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 아데노 관련 바이러스 벡터 제조 시장 보고서는 약 69개의 표, 71개의 그림, 188페이지 분량입니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global adeno-associated virus vectors manufacturing market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.
Adeno-associated viral (AAV) vectors are replication-defective, single-stranded DNA parvoviruses, which require a helper Ad for their replication. Site-specific or random AAV vector integration into the host cell genome, in the absence of a helper virus, results in long-term transgene expression. Additionally, adeno-associated viral vectors demonstrate high transduction efficiency in a broad range of quiescent and dividing target cells. In contrast to Ads, AAV vectors do not produce a significant immune response.
Moreover, adeno-associated viral vectors are more frequently used for gene therapy for genetic diseases and cancer. In addition, adeno-associated virus vector-mediated gene delivery is also approved for the treatment of inherited blindness and spinal muscular atrophy, long-term therapeutic effects and other rare diseases, including hemophilia and Duchenne muscular dystrophy. They are also considered in cell therapy and vaccine production to treat many diseases.
Market Dynamics: Drivers
Increasing adoption of adeno-associated viral vectors
The increasing adoption of adeno-associated viral vectors is expected to drive the market over the forecast period. The increasing adoption leads to an increasing focus on launching more manufacturing platforms. For instance, on May 16, 2023, AGC Biologics launched its BravoAAV and ProntoLVV viral vector platforms. Leveraging three decades of Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing and analytical experience, AGC Biologics’ new platforms offer fast, efficient and reproducible clinical and commercial GMP production and release.
Additionally, on October 10, 2022, Charles River Laboratories International, Inc. launched its nAAVigation Vector Platform (nAAVigation). Leveraging decades of Adeno-Associated Virus (AAV) vector contract development and manufacturing (CDMO) experience and biologics testing expertise, Charles River has established a platform that streamlines the pathway to GMP AAV vector manufacturing without the need for significant process development.
Moreover, the adeno-associated viral vectors are mostly used to treat many diseases, this further increases the adoption of adeno-associated virus vectors. For instance, on March 02, 2023, the first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna, Spark Therapeutics vision loss cure, and Zolgensma, Novartis’ spinal muscular atrophy treatment. In addition, they brought about a surge in demand for gene therapy delivery technologies. The surge is ongoing. Currently, it is stimulating innovation in vector design and manufacturing.
Furthermore, adeno-associated virus vectors are most commonly applicable for gene therapy, which also further increases the adoption. For instance, on March 9, 2023, Charles River Laboratories International, Inc. launched its off-the-shelf pHelper offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.
Further, the increasing prevalence of genetic, infectious, neurological, ophthalmic and other chronic disorders, rising FDA approvals, increasing clinical trials, increasing awareness and advancements in the development novel therapies and vaccines are the factors expected to drive the market over the forecast period.
Restraints
Factors such as high manufacturing costs, lack of skilled professionals and limited cloning capacity are expected to hamper the market.
Segment Analysis
The global adeno-associated virus vectors manufacturing market is segmented based on method, application, therapeutic area, end-user and region.
The gene therapy segment accounted for approximately 43.2% of the adeno-associated virus vectors manufacturing market share
The gene therapy segment is expected to hold the largest market share over the forecast period. Adeno-associated virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. Adeno-associated virus (AAV) vectors are currently among the most frequently used viral vectors for gene therapy. Many companies are focussing on adeno-associated virus vector manufacturing for gene therapy.
For instance, on February 23, 2021, SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs.
Additionally, on August 1, 2023, Waters Corporation introduced the first in a new line of size exclusion chromatography (SEC) columns aimed at improving the analysis while lowering the cost of gene therapies, specifically adeno-associated viral (AAV) vectors. The new Waters XBridge Premier GTx BEH SEC columns double the speed of measuring the potency and safety of AAVs and optimize the manufacturing of these novel gene delivery vehicles.
Moreover, adeno-associated virus vectors helps researchers for developing gene therapies to treat many serious disorders. For instance, in November 2022, PerkinElmer, Inc., a global leader committed to innovating for a healthier world, launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer.
Geographical Analysis
North America accounted for approximately 40.3% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is known for its strong presence of major players such as biotechnology companies and pharmaceutical companies. The presence of major players actively focussing on manufacturing more advanced adeno-associated virus vectors by offering advantages such as cost-effectiveness.
For instance, on November 16, 2022, Thermo Fisher Scientific, the world leader in serving science, introduced the Gibco CTS AAV-MAX Helper-Free AAV Production System, a new all-in-one solution designed to help meet clinical and commercial demands for cost-effective and scalable development of adeno-associated virus (AAV)-based gene therapies. It is the only product of its kind that is manufactured under cGMP conditions to enable large-scale applications.
Furthermore, increasing research activities in the region helps to manufacture more advanced virus vectors which are more advantageous for gene therapy. As research activities increase, gene therapies are developed more precisely by offering wide treatment options for many diseases, which results in better patient outcomes.
For instance, on February 15, 2022, Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, launched three advanced affinity chromatography resins for use in gene therapy manufacturing workflows. The resins AVIPure - AAV9, AVIPure - AAV8, and AVIPure - AAV2 – were developed by Avitide LLC, a Repligen company, and are specific to the major adeno-associated virus (AAV) gene therapy vectors.
Competitive Landscape
The major global players in the adeno-associated virus vectors manufacturing market include Thermo Fisher Scientific Inc., Oxford Biomedica PLC, Lonza Ltd, uniQure N.V., FUJIFILM Diosynth Biotechnologies, SIRION Biotech GmbH, Curigin Inc., Pfizer Inc., Genscript Biotech Corp and Vector Biolabs among others.
Key Developments
• On March 27, 2023, Avirmax CMC Inc. a cGMP-licensed contract development and manufacturing organization (CDMO), implemented its newly developed Sf rhabdovirus-free cell lines (under the generic trademark of Sf-RVF) developed for producing recombinant adeno-associated viral vectors (rAAV).
• On August 30, 2023, Quest Diagnostics granted FDA breakthrough designation for its adeno-associated virus (AAV) test, AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). Breakthrough Device Designation is an FDA process designed to expedite the development and review of certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
• On June 15, 2022, Exothera SA collaborated with LogicBio Therapeutics and Polyplus-transfection SA. for the development of a highly scalable AAV manufacturing platform with a capacity from 200 L to 2,000 L.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global adeno-associated virus vectors manufacturing market. The pandemic has created a surge in demand for adeno-associated viral vectors, particularly in the development and production of COVID-19 vaccines. The urgent need for large-scale manufacturing of these vectors to support vaccine development has led to increased demand.
For instance, according to the National Institute of Health (NIH), 2022, based on the study, they developed a type 9 adeno-associated virus vectored vaccine candidate expressing a dimeric receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S protein) and evaluated its immunogenicity in a murine model. The vaccine candidate, named AAV9-RBD virus, was constructed by inserting a signal peptide to the N-terminus of two copies of RBD, spaced by a linker, into the genome of a type 9 adeno-associated virus.
Market Segmentation
By Method
• In Vivo
• In Vitro
By Application
• Gene Therapy
• Cell Therapy
• Vaccine Production
• Others
By Therapeutic Area
• Genetic Disorders
• Infectious Diseases
• Neurological Disorders
• Hematological Diseases
• Ophthalmic Disorders
• Others
By End-User
• Pharmaceutical Companies
• Biotechnology Companies
• Academic and Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global adeno-associated virus vectors manufacturing market segmentation based on method, application, therapeutic area, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of adeno-associated virus vectors manufacturing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global adeno-associated virus vectors manufacturing market report would provide approximately 69 tables, 71 figures, and 188 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Method
3.2. Snippet by Application
3.3. Snippet by Therapeutic Area
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption of Adeno-Associated Viral Vectors
4.1.2. Restraints
4.1.2.1. High Manufacturing Costs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Method
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
7.1.2. Market Attractiveness Index, By Method
7.2. In Vivo*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. In Vitro
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Gene Therapy*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cell Therapy
8.4. Vaccine Production
8.5. Others
9. By Therapeutic Area
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
9.1.2. Market Attractiveness Index, By Therapeutic Area
9.2. Genetic Disorders*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Infectious Diseases
9.4. Neurological Disorders
9.5. Hematological Diseases
9.6. Ophthalmic Disorders
9.7. Others
10. By End-User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.1.2. Market Attractiveness Index, By End-User
10.2. Pharmaceutical Companies*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Biotechnology Companies
10.4. Academic and Research Institutes
10.5. Others
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Method
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Thermo Fisher Scientific Inc.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. Oxford Biomedica PLC
13.3. Lonza Ltd
13.4. uniQure N.V.
13.5. FUJIFILM Diosynth Biotechnologies
13.6. SIRION Biotech GmbH
13.7. Curigin Inc.
13.8. Pfizer Inc.
13.9. Genscript Biotech Corp
13.10. Vector Biolabs
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Thermo Fisher Scientific Inc., 4.	Key Developments, Oxford Biomedica PLC, Lonza Ltd, uniQure N.V., FUJIFILM Diosynth Biotechnologies, SIRION Biotech GmbH, Curigin Inc., Pfizer Inc., Genscript Biotech Corp, Vector Biolabs

표 목록 (Tables)

List of Tables

Table 1 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 8 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 10 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 12 Global Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 14 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Adeno Associated Virus Vectors Manufacturing Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 17 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 18 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 19 North America Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 North America Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 22 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 23 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 24 South America Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 25 South America Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 27 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 28 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 29 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 30 Europe Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Value, By Method, 2022-2031 (US$ Million)

Table 37 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Value, By Application, 2022-2031 (US$ Million)

Table 38 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Value, By Therapeutic Area, 2022-2031 (US$ Million)

Table 39 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Value, By End-User, 2022-2031 (US$ Million)

Table 40 Thermo Fisher Scientific Inc.: Overview

Table 41 Thermo Fisher Scientific Inc.: Product Portfolio

Table 42 Thermo Fisher Scientific Inc.: Key Developments

Table 43 Oxford Biomedica PLC: Overview

Table 44 Oxford Biomedica PLC: Product Portfolio

Table 45 Oxford Biomedica PLC: Key Developments

Table 46 Lonza Ltd: Overview

Table 47 Lonza Ltd: Product Portfolio

Table 48 Lonza Ltd: Key Developments

Table 49 uniQure N.V.: Overview

Table 50 uniQure N.V.: Product Portfolio

Table 51 uniQure N.V.: Key Developments

Table 52 FUJIFILM Diosynth Biotechnologies: Overview

Table 53 FUJIFILM Diosynth Biotechnologies: Product Portfolio

Table 54 FUJIFILM Diosynth Biotechnologies: Key Developments

Table 55 SIRION Biotech GmbH: Overview

Table 56 SIRION Biotech GmbH: Product Portfolio

Table 57 SIRION Biotech GmbH: Key Developments

Table 58 Curigin Inc.: Overview

Table 59 Curigin Inc.: Product Portfolio

Table 60 Curigin Inc.: Key Developments

Table 61 Pfizer Inc.: Overview

Table 62 Pfizer Inc.: Product Portfolio

Table 63 Pfizer Inc.: Key Developments

Table 64 Genscript Biotech Corp: Overview

Table 65 Genscript Biotech Corp: Product Portfolio

Table 66 Genscript Biotech Corp: Key Developments

Table 67 Vector Biolabs: Overview

Table 68 Vector Biolabs: Product Portfolio

Table 69 Vector Biolabs: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 2 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 & 2031 (%)

Figure 3 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 & 2031 (%)

Figure 5 Global Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 6 Global Adeno Associated Virus Vectors Manufacturing Market Share, By Region, 2022 & 2031 (%)

Figure 7 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Method, 2022-2031 (%)

Figure 8 In Vivo Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 9 In Vitro Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 10 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 11 Gene Therapy Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 12 Cell Therapy Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 13 Vaccine Production Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 14 Others Application in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 15 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Therapeutic Area, 2022-2031 (%)

Figure 16 Genetic Disorders Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 17 Infectious Diseases Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 18 Neurological Disorders Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 19 Hematological Diseases Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 20 Ophthalmic Disorders Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 21 Others Therapeutic Area in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 22 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By End-User, 2022-2031 (%)

Figure 23 Pharmaceutical Companies End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 24 Biotechnology Companies End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 25 Academic and Research Institutes End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 26 Others End-User in Global Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 27 Global Adeno Associated Virus Vectors Manufacturing Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 28 North America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 29 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 30 Europe Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 31 South America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 32 Middle East and Africa Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 33 North America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 34 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 & 2031 (%)

Figure 35 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 36 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 & 2031 (%)

Figure 37 North America Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 38 North America Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 39 South America Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 40 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 & 2031 (%)

Figure 41 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 42 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 & 2031 (%)

Figure 43 South America Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 44 South America Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 45 Europe Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 46 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 & 2031 (%)

Figure 47 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 48 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 & 2031 (%)

Figure 49 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 50 Europe Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 51 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 52 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 & 2031 (%)

Figure 53 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 54 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 & 2031 (%)

Figure 55 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 56 Asia-Pacific Adeno Associated Virus Vectors Manufacturing Market Share, By Country, 2022 & 2031 (%)

Figure 57 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Value, 2022-2031 (US$ Million)

Figure 58 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Share, By Method, 2022 & 2031 (%)

Figure 59 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Share, By Application, 2022 & 2031 (%)

Figure 60 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Share, By Therapeutic Area, 2022 & 2031 (%)

Figure 61 Middle East & Africa Adeno Associated Virus Vectors Manufacturing Market Share, By End-User, 2022 & 2031 (%)

Figure 62 Thermo Fisher Scientific Inc.: Financials

Figure 63 Oxford Biomedica PLC: Financials

Figure 64 Lonza Ltd: Financials

Figure 65 uniQure N.V.: Financials

Figure 66 FUJIFILM Diosynth Biotechnologies: Financials

Figure 67 SIRION Biotech GmbH: Financials

Figure 68 Curigin Inc.: Financials

Figure 69 Pfizer Inc.: Financials

Figure 70 Genscript Biotech Corp: Financials

Figure 71 Vector Biolabs: Financials

글로벌 아데노 관련 바이러스 벡터 제조 시장 – 2023-2030

Global Adeno Associated Virus Vectors Manufacturing Market - 2023-2030